Kingsview Wealth Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
FCBT
EP
Kingsview Wealth Management's XPH Position: Q2 2026 in Review
Kingsview Wealth Management increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 6.6% in Q2 2026, buying an estimated $1.15M and bringing the position to 314,894 shares worth $20.9M. The position accounts for 0.25% of the portfolio, ranked #71.
Kingsview Wealth Management first reported a position in XPH in Q1 2023 and has held it in 10 quarters since. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.
- Kingsview Wealth Management held 314,894 shares of State Street SPDR S&P Pharmaceuticals ETF worth $20.9M as of Q2 2026.
- Kingsview Wealth Management bought 19,629 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $1.15M.
- State Street SPDR S&P Pharmaceuticals ETF made up 0.25% of Kingsview Wealth Management's portfolio in Q2 2026, its #71 holding.
- Kingsview Wealth Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2023 and has held it in 10 quarters since.
- 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.
Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.